



# HIGHEST ESMO-MCBS SCORES

among CDK4/6 inhibitors\*<sup>1-5</sup>

1L Pre-menopausal<sup>#</sup>

**PERFECT  
SCORE**

**5**

1L Post-menopausal<sup>^</sup>

**SCORES  
OF**

**4**

**KISQALI**<sup>®</sup> demonstrates consistent **Survival Benefit** and improved or preserved **QoL**\*<sup>1-3,6-9</sup>

\*For all 1L HR+/HER2- aBC patients | <sup>#</sup>KISQALI + AI + GOS | <sup>^</sup>KISQALI + AI or FUL

1L, first-line; aBC, advanced breast cancer; AI, aromatase inhibitor; ESMO, European Society for Medical Oncology; FUL, fulvestrant; GOS, goserelin; HER2-, human epidermal growth factor receptor 2- negative; HR+, hormone receptor-positive; MCBS, Magnitude of Clinical Benefit Scale; QoL, quality of life.

**References:**

1. ESMO-MCBS Scorecards - Ribociclib (MONALEESA-2) [Internet]. ESMO. 2022 [cited 15 July 2022]. Available from: <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1>. 2. ESMO-MCBS Scorecards - Ribociclib (MONALEESA-3) [Internet]. ESMO. 2022 [cited 15 July 2022]. Available from: <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-161-1>. 3. ESMO-MCBS Scorecards - Ribociclib (MONALEESA-3) [Internet]. ESMO. 2022 [cited 15 July 2022]. Available from: <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1>. 4. ESMO-MCBS Scorecards - Palbociclib (PALOMA-2) [Internet]. ESMO. 2022 [cited 15 July 2022]. Available from: <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-7-1>. 5. ESMO-MCBS Scorecards - Abemaciclib (MONARCH-3) [Internet]. ESMO. 2022 [cited 15 July 2022]. Available from: <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-159-1>. 6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386:942-50. 7. Neven P, Fasching PA, Chia S, et al. Updated overall survival results from the first-line population in the phase III MONALEESA-3 Trial of postmenopausal patients with HR+/HER2+ advanced breast cancer treated with ribociclib + fulvestrant. Presented at: European Society of Medical Oncology; May 3-5, 2022. 8. Tripathy D, Im S-A, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) + ribociclib. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2020; San Antonio, TX. Poster PD2-04. 9. ESMO-Magnitude of Clinical Benefit Scale (V1.1). <https://www.esmo.org/content/download/288505/5736229/1/ESMO-MCBS-Factsheet.pdf>. [cited 15 July 2022].



**For healthcare professionals only.**

Please visit <https://www.novartis.com.sg/product-list/kisqali> to access or download the Package Insert. Alternatively, please scan this code for more information about this medicine.